Healthcare / Diagnostics & ResearchMCE
$58.00
-1.40 (-2.36%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 22% · confianza 25%
FCF escenarios
weak_data · normalized FCF $36.0M · quality 78.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
64/100
B
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$929M
P/E
21.2x
↑EV/EBITDA
11.5x
↓ROE
38.2%
↑Gross Margin
88.7%
↑Debt/Equity
0.64
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+15.0%
FCF CAGR
+6.0%
FCF margin
15.5%
FCF / Net income
1.11x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $301.8M · net income $42.1M · FCF $46.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $301.8M | $301.8M | $262.6M | $224.9M | $198.4M |
| Net Income | $42.1M | $42.1M | $40.2M | $36.0M | $29.5M |
| EBITDA | $86.3M | $86.3M | $78.1M | $67.2M | $56.1M |
| EPS | 2.58 | 2.58 | 2.47 | 2.21 | 1.81 |
| Gross Margin | 88.7% | 88.7% | 88.4% | 88.0% | 87.1% |
| Operating Margin | 20.1% | 20.1% | 21.2% | 22.2% | 21.2% |
| Net Margin | 13.9% | 13.9% | 15.3% | 16.0% | 14.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.64 | 0.64 | 0.65 | 0.52 | 0.71 |
| Current Ratio | 0.96 | 0.96 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $46.8M | $46.8M | $36.0M | $35.1M | $39.3M |
| Returns | |||||
| ROE | 38.2% | 38.2% | 41.5% | 39.5% | 43.8% |
| Valuation | |||||
| P/E | 21.17 | 21.17 | 13.28 | 10.41 | 9.97 |
| EV/EBITDA | 11.52 | 11.52 | 7.40 | 6.16 | 5.76 |
| P/B | 8.44 | 8.44 | 5.42 | 4.12 | 4.37 |
| Growth & Yield | |||||
| Revenue Growth | 14.9% | 14.9% | 16.8% | 13.3% | — |
| EPS Growth | 4.5% | 4.5% | 11.8% | 22.1% | — |
| Dividend Yield | 2.7% | 2.7% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
25.9%
EPS terminal req.
$5.15
Spread vs growth
-21.4%
5Y implied EPS CAGR
19.3%
EPS terminal req.
$6.23
Spread vs growth
-14.8%
10Y implied EPS CAGR
14.5%
EPS terminal req.
$10.03
Spread vs growth
-10.1%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+41.1%
Start / end P/E
17.0x → 22.5x
EPS bridge
2.47 → 2.58
Residual
+1.4%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.